Skip to main content Accessibility help
×
Home
Hostname: page-component-78dcdb465f-w78fb Total loading time: 1.016 Render date: 2021-04-17T06:27:25.535Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Jose de Leon, MD

Published online by Cambridge University Press:  07 November 2014

Abstract

Although most patients with depression ultimately respond to antidepressant therapy, >50% have inadequate response to an individual antidepressant trial. The desire to avoid adverse drug reactions is common among patients, and is an important determinant of drug selection among psychiatrists. However, since the major classes of antidepressants and antipsychotics appear to be comparable in efficacy, clinicians have little basis for selecting the most effective agent for an individual patient. Pharmacogenetics, often described as the study of genetic variation that explains differential response to medication, represents an important new avenue toward improving treatment outcomes. Genetic variation in drug-metabolizing enzymes has been recognized for decades. The main focus of current psychiatric pharmacogenetic testing is on the cytochrome P450 (CYP) 2D6 and, to a somewhat lesser extent, on the 2C19 genes. Data suggest that poor metabolizer status can be associated with an increased risk of adverse drug reactions with certain medications, and that ultra-rapid metabolizers may require higher-than-usual doses to achieve a therapeutic response. The importance of CYP enzymes in the metabolism of several antidepressant and antipsychotic drugs suggest that genetic variation may aid in medication selection or dosing. Advances in pharmacogenetic research may facilitate the development of personalized medicine in which genetic information can inform drug selection, leading to optimal drug effectiveness and minimal drug toxicity.

In this monograph, David A. Mrazek, MD, provides an overview of the context of genetic testing in clinical psychiatric practice. Next, Jordan W. Smoller, MD, ScD, discusses some of the practical issues related to medication selection. Finally, Jose de Leon, MD, presents a comprehensive review of antidepressant and antipsychotic treatment based on drug metabolism, and reviews the available testing methods for CYP 2D6 and 2C19 genotypes.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below.

References

1.de Leon, J, Armstrong, SC, Cozza, KL. Clinical guidelines for using pharmacogenetic testing of CYP450 2D6 and CYP450 2C19 in psychiatry. Psychosomatics. 2006;47:7585.CrossRefGoogle Scholar
2.Kirchheiner, J, Nickchen, K, Bauer, M, et al.Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442473.CrossRefGoogle ScholarPubMed
3.Skinner, MH, Kuan, HY, Pan, A, et al.Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170177.CrossRefGoogle Scholar
4.Kubo, M, Koue, T, Inaba, A, et al.Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic Aripiprazole. Drug Metab Pharmacokinet. 2005;20:5564.CrossRefGoogle ScholarPubMed
5.de Leon, J, Dinsmore, L, Wedlund, PJ. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers (letter). J Clin Psychopharmacol. 2003;23:420421.CrossRefGoogle Scholar
6. de Leon, J, Armstrong, SC, Cozza, KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262273.CrossRefGoogle ScholarPubMed
7.Daly, AK. Development of analytical technology in pharmacogenetic research. Naunyn-Schmiedeberg's Arch Pharmacol. 2004;369:133140.CrossRefGoogle ScholarPubMed
8. Roche Molecular Systems, Inc. AmpliChip CYP450 test for in vitro diagnostic use. Branchburg, NJ: Roche Molecular Systems, Inc.; 2005.Google Scholar
9.de Leon, J, Susce, MT, Murray-Carmichael, E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006. In press.Google Scholar
10. Blue Cross and Blue Shield Association. Special Report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. Tec Assessment Program Vol 19, No. 9, December 2004. Available at: htpp://www.bcbs.com/tec/vol19/19._09.pdf. Accessed September 13, 2005.Google Scholar
11.Johansson, I, Lundqvist, E, Bertilsson, L, et al.Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:1182511829.CrossRefGoogle ScholarPubMed
12.Ernst, FR, Grizzle, AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192199.Google ScholarPubMed
13.Chou, WH, Yan, FX, de Leon, J, et al.An extension of a pilot study: impact from the cytochrome P450-2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. J Clin Psychopharmacol. 2000;20:246251.CrossRefGoogle ScholarPubMed
14.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005;353:12091223.CrossRefGoogle ScholarPubMed
15. Roses, AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev. 2004;5:645656CrossRefGoogle ScholarPubMed
16.de Leon, J, Susce, MT, Pan, R-M, et al.The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:1527.CrossRefGoogle ScholarPubMed
17.Alfaro, CL, Lam, YW, Simpson, J, et al.CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155163.CrossRefGoogle ScholarPubMed
18.de Leon, J. The AmpliChip CYP 450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006. In press.Google Scholar
19.Lertola, J. Deciphering the code and what might come from it. Time. 1999; Nov 8:6869.Google Scholar
20.Collins, FS, McKusick, VA. Implications of the human genome project for medical science. JAMA. 2001;285:540544.CrossRefGoogle ScholarPubMed
21. FDA. FDA clears genetic test that advances personalized medicine. Test helps determine safety of drug therapy. Available at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW012220.html. Accessed February 14, 2006.Google Scholar
22.Ruaño, G, Thompson, PD, Windemuth, A, et al.Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics. 2005;6:865872.CrossRefGoogle ScholarPubMed
23.Baca-Garcia, E, Perez-Rodriguez, MM, Basurte-Villamor, I, et al.Using data mining to explore complex clinical decisions: a study of hospitalization after a suicide attempt. J Clin Psychiatry. 2006. In press.Google Scholar
24.Emery, J, Hayflick, S. The challenge of integrating genetic medicine into primary care. BMJ. 2001;322:10271030.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 13 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 17th April 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Jose de Leon, MD
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Jose de Leon, MD
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Jose de Leon, MD
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *